| Type | Public (NASDAQ: BCRX) |
|---|---|
| Industry | Healthcare |
| Founded | 1986 |
| Headquarters | Birmingham, Alabama, USA |
| Key people | Jon P. Stonehouse , President and Chief Executive Officer Stuart Grant, Chief Financial Officer |
| Products | Biotechnology |
| Revenue | US$16.7M (FY 2010)[1] |
| Operating income | US$-10.3M (FY 2010)[1] |
| Net income | US$-10.2M (FY 2010)[1] |
| Total assets | US$109M (FY 2010)[2] |
| Total equity | US$65.5M (FY 2010)[2] |
| Employees | 80 (2008) |
| Website | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Birmingham, Alabama.[3] The company focuses on cancer, autoimmune diseases, and viral infections.[3] The company's most notable function has been the production of the antiviral medication Peramivir, which was approved by the FDA for emergency use in the treatment of drug resistant influenza A virus subtype H1N1.[4]
Contents |
The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an Initial Public Offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.[5]
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006.[6]